Pharmathen launches will bolster its profits

Launching a wave of generic long-acting injectables from next year followed by value-added, 505(b)(2) injectables will see Pharmathen deliver annual earnings before interest, tax, depreciation and amortisation (EBITDA) of more than €100 million (US$114 million) in the “near term”, the Netherlands-based firm believes.